Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trade Groups Make AER Legislation Wish List; Preemption Is Top Priority

This article was originally published in The Tan Sheet

Executive Summary

Federal legislation requiring mandatory adverse event reporting for dietary supplements is both "likely" and "good" but must include preemption of state laws, trade groups asserted during a "State of the Industry" seminar Nov. 11 at SupplySide West in Las Vegas

You may also be interested in...



History Says Industry Needs Post-AER Bill Response Plan – Ullman

The dietary supplement industry needs to have a "mechanism in place" to respond to actions industry opponents are likely to take following the passage of an AER bill, attorney Marc Ullman suggested at the SupplySide East trade show and conference in Secaucus, N.J. May 3

History Says Industry Needs Post-AER Bill Response Plan – Ullman

The dietary supplement industry needs to have a "mechanism in place" to respond to actions industry opponents are likely to take following the passage of an AER bill, attorney Marc Ullman suggested at the SupplySide East trade show and conference in Secaucus, N.J. May 3

History Says Industry Needs Post-AER Bill Response Plan – Ullman

The dietary supplement industry needs to have a "mechanism in place" to respond to actions industry opponents are likely to take following the passage of an AER bill, attorney Marc Ullman suggested at the SupplySide East trade show and conference in Secaucus, N.J. May 3

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel